Ionis Pharmaceuticals, Inc. (IONS) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Ionis Pharmaceuticals, Inc. (IONS) closed at USD 42.70 on 2026-10-14, a change of -42 % over the past year, with a market capitalization of USD 7.33B.

Ionis Pharmaceuticals, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Ionis Pharmaceuticals, Inc. key figures

Previous close

USD 42.70 (2026-10-14)

1-year change

-42 %

Market cap

USD 7.33B

Enterprise value

USD 7.42B

P/E ratio (trailing)

-12.68

P/E ratio (forward)

-39.67

EPS (trailing)

-3.48

EPS (forward)

-1.11

PEG ratio

27.33

Price to book

16.62

Revenue growth

-40.7 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

5.07

Employees

1,480

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 which is in Phase 3 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Ionis Pharmaceuticals, Inc. and compare it with other stocks.